|
|
 |
|
|
|
|
15. J. A. DiMasi. Success rates for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther. 58: 114, 1995. |
|
|
|
|
|
|
|
|
16. L. B. Sheiner. The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther. 50: 49, 1991. |
|
|
|
|
|
|
|
|
17. L. B. Sheiner. A new paradigm for clinical drug development. Submitted. |
|
|
|
|
|
|
|
|
18. C. C. Peck, W. H. Barr, L. Z. Benet, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51: 465473, 1992. |
|
|
|
|
|
|
|
|
19. M. Sale, L. B. Sheiner, P. Volberding, and T. F. Blaschke. Zidovudine response relationships in early human immunodeficiency virus infection. Clin. Pharmacol. Ther. 54: 556566, 1993. |
|
|
|
|
|